



Substitute for form 1449A&B/PTO				Complete if Known	
				Application Number	10/614,037
				Filing Date	07/08/2003
				First Named Inventor	REITER et al.
				Art Unit	1636
				Examiner Name	N. VOGEL
Sheet	1	of	16	Attorney Docket Number	14693-0195

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
1	US-2002/0182679-A1		12-05-2002	Reiter et al.	
2	US-2003/0203448-A1		10-30-2003	Reiter et al.	
3	US-4,431,629		02-14-1984	Olsen	
4	US-4,443,540		04-17-1984	Chervan et al.	
5	US-4,767,704		08-30-1988	Cleveland et al.	
6	US-4,978,616		12-18-1990	Dean, Jr. et al.	
7	US-5,122,469-A		06-16-1992	Mather et al.	
8	US-5,316,938-A		05-31-1994	Keen et al.	
9	US-5,378,612-A		01-03-1995	Nakashima et al.	
10	US-5,393,668-A		02-28-1995	Cinatl et al.	
11	US-5,441,868-A		08-15-1995	Lin	
12	US-5,573,937-A		11-12-1996	Shinmoto et al.	
13	US-5,633,162-A		05-27-1997	Keen et al.	
14	US-5,719,050-A		02-17-1998	Hashimoto et al.	
15	US-5,741,705-A		04-21-1998	Blom et al.	
16	US-5,789,247-A		08-04-1998	Bailey et al.	
17	US-5,811,299-A		09-22-1998	Renner et al.	
18	US-5,851,800-A		12-22-1998	Adamson et al.	
19	US-5,885,835-A		03-23-1999	Blom et al.	
20	US-6,048,728-A		04-11-2000	Inlow et al.	
21	US-6,100,061-A		08-08-2000	Reiter et al.	
22	US-6,475,725-B1		11-05-2002	Reiter et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Filed On/Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	
				MM-DD-YYYY	
	23	WO	85/02610	A1	06-20-1985
	24	WO	86/04920	A1	08-28-1986

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/614,037
(Use as many sheets as necessary)				Filing Date	07/08/2003
				First Named Inventor	REITER et al.
				Art Unit	1636
				Examiner Name	N. VOGEL
Sheet	2	of	16	Attorney Docket Number	14693-0195

FOREIGN PATENT DOCUMENTS							
Examiner Initials ²	Cite No. ¹	Foreign Patent Document		Filed On/Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³	Number ⁴				
	25	WO	88/00867	A1	02-11-1988	The University of New South Wales et al.	<input type="checkbox"/>
	26	WO	89/00192	A1	01-12-1989	Amgen Inc.	<input type="checkbox"/>
	27	WO	91/09122	A1	06-27-1991	Kabivitrum AB	<input type="checkbox"/>
	28	WO	91/10726	A1	07-11-1991	The United States of America Represented by the Secretary, United States Department of Commerce	<input type="checkbox"/>
	29	WO	94/25599	A1	11-10-1994	Gesellschaft Für Biotechnologische Forshung MBH	Translation of Abstract Only <input type="checkbox"/>
	30	WO	98/07730	A2, A3	03-14-1996	Renner et al.	Translation of Abstract Only <input type="checkbox"/>
	31	WO	98/15231	A1	05-21-1996	Immunoaktiengesellschaft	<input type="checkbox"/>
	32	WO	98/18734	A1	06-20-1996	Ciba-Geigy AG	<input type="checkbox"/>
	33	WO	96/26266	A1	08-13-1996	Quest International B.V.	<input type="checkbox"/>
	34	WO	96/40866	A1	12-19-1996	Sandoz Ltd. et al.	<input type="checkbox"/>
	35	WO	97/05240	A1	02-13-1997	Unisearch Limited et al.	<input type="checkbox"/>
	36	WO	98/08934	A1	03-05-1998	Life Technologies, Inc.	<input type="checkbox"/>
	37	WO	98/15614	A1	04-16-1998	Life Technologies, Inc.	<input type="checkbox"/>
	38	WO	98/54298	A1	12-03-1998	Chiron S.p.A.	<input type="checkbox"/>
	39	WO	99/05268	A1	02-04-1999	Boehringer Mannheim GmbH	Translation of Abstract Only <input type="checkbox"/>
	40	WO	99/57246	A1	11-11-1999	Life Technologies, Inc.	<input type="checkbox"/>
	41	WO	00/03000	A2	01-20-2000	Chugai Seiyaku Kabushiki Kaisha et al.	<input type="checkbox"/>
	42	WO	01/11021	A1	02-15-2001	Baxter Aktiengesellschaft	Translation of Abstract Only <input type="checkbox"/>
	43	WO	01/14529	A1	03-01-2001	Immunex Corporation	<input type="checkbox"/>
	44	WO	01/23527	A1	04-05-2001	Baxter Aktiengesellschaft	<input type="checkbox"/>
	45	WO	02/24876	A2, A3	03-28-2002	Polymun Scientific Immunbiologische Forschung GmbH	<input type="checkbox"/>
	46	WO	2004/005493	A1	01-15-2004	Baxter International, Inc. et al.	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete If Known	
Sheet	3	of	16	Application Number	10/614,037
				Filing Date	07/08/2003
				First Named Inventor	REITER et al.
				Art Unit	1636
				Examiner Name	N. VOGEL
				Attorney Docket Number	14693-0195

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Filed On/Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
47	AT	1659/99	A		09-28-1999	Baxter Aktiengesellschaft Wien		<input checked="" type="checkbox"/>
48	AU	78958/98	A		10-08-1998	Wolf		<input type="checkbox"/>
49	CA	2,161,517	A1		11-10-1994	Wolf		<input type="checkbox"/>
50	EP	00 120 896.6			09-25-2000	Polymun Scientific Immunobiologische Forschung GmbH		<input type="checkbox"/>
51	EP	0 160 457	B1		11-06-1985	Genetech, Inc.		<input type="checkbox"/>
52	EP	0 481 791	A2		04-22-1992	The Wellcome Foundation Limited		<input type="checkbox"/>
53	EP	0 485 689	A1		05-20-1992	Rikagaku Kenkyusho		<input type="checkbox"/>
54	EP	0 631 731	A1		01-04-1995	Bristol-Myers Squibb Company		<input type="checkbox"/>
55	EP	0 666 312	A1		08-09-1995	Renner Wolfgang et al.		<input type="checkbox"/>
56	EP	0 711 835	A1		05-15-1996	Immuno AG	Translation of Abstract Only	<input type="checkbox"/>
57	EP	0 872 487	A2		10-21-1998	Bayer Corporation		<input type="checkbox"/>
58	FR	2 196 388	A		03-15-1974	Cudennec		<input type="checkbox"/>
59	JP	2-859679	B2		Unknown	Unknown		<input checked="" type="checkbox"/>
60	JP	3-244391			10-10-1991	Ajinomoto KK		<input type="checkbox"/>
61	JP	4-316484			11-06-1992	Chemo Sero Therapeut. Res. Inst. et al.	Translation of Abstract Only	<input type="checkbox"/>
62	JP	5-123178	A		05-17-1993	Ajinomoto KK		<input type="checkbox"/>
63	JP	7-039388	A		02-09-1995	Bio Polymer Res KK		<input type="checkbox"/>
64	JP	H01-211488	A		08-24-1999	The Director of the Agency of Industrial Science and Technology		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
Examiner Signature				Date Considered		

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
				Application Number	10/614,037
				Filing Date	07/08/2003
				First Named Inventor	REITER et al.
				Art Unit	1636
				Examiner Name	N. VOGEL
Sheet	4	of	16	Attorney Docket Number	14693-0195

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	65	BERG, D.T. et al.; "High-Level Expression of Secreted Proteins from Cells Adapted to Serum-Free Suspension Culture"; <u>BioTechniques</u> ; 1993; Vol. 14(6); pp. 972-978.			<input type="checkbox"/>
	66	BIELICKI, J. et al.; "Recombinant Human Sulphamidase: Expression, Amplification, Purification and Characterization"; 1998; <u>Biochem. J.</u> ; Vol. 329; pp. 145-150.			<input type="checkbox"/>
	67	BROWN, M.E. et al.; "Process Development for the Production of Recombinant Antibodies Using the Glutamine Synthetase (GS) System"; 1992; <u>Cytotechnology</u> ; Vol. 9; pp. 231-236.			<input type="checkbox"/>
	68	BURGER, C. et al.; "An Integrated Strategy for the Process Development of a Recombinant Antibody-Cytokine Fusion Protein Expressed in BHK Cells"; 1999; <u>Appl. Microbiol. Biotechnol.</u> ; Vol. 52; pp. 345-353.			<input type="checkbox"/>
	69	CARTIER, M. and STANNERS, C.P.; "Stable, High-Level Expression of a Carcinoembryonic Antigen-encoding cDNA After Transfection and Amplification with the Dominant and Selectable Asparagine Synthetase Marker"; 1990; <u>Gene</u> ; Vol. 95; pp. 223-230.			<input type="checkbox"/>
	70	COLE, E.S. et al.; "Recombinant Human Thyroid Stimulating Hormone: Development of a Biotechnology Product for Detection of Metastatic Lesions of Thyroid Carcinoma"; September 1993; <u>Biotechnology</u> ; Vol. 11; pp. 1014-1024.			<input type="checkbox"/>
	71	CRUZ, H.J. et al.; "Adaptation of BHK Cells Producing a Recombinant Protein to Serum-Free Media and Protein-Free Medium"; 1998; <u>Cytotechnology</u> ; Vol. 26; pp. 59-64.			<input type="checkbox"/>
	72	DONALDSON, M.S. and SCULER, M.L.; "Low-Cost Serum-Free Medium for the BTI-Tn5B1-4 Insect Cell Line"; 1998; <u>Biotechnol. Prog.</u> ; Vol. 14; pp. 573-579.			<input type="checkbox"/>
	73	DOYLE, A. et al. eds.; "Cloning"; Part 4D Module 4D1 <i>In Cell & Tissue Culture: Laboratory Procedures</i> ; 1998; John Wiley & Sons; London; Cloning Techniques (Non-hybridoma Related); pp. 4D:1.1-4D:1.9.			<input type="checkbox"/>
	74	EAGLE, H.; "Amino Acid Metabolism in Mammalian Cell Cultures"; August 21, 1939; <u>Science</u> ; Vol. 130; pp. 432-437.			<input type="checkbox"/>
	75	FARRELL, P.J. et al.; "High-Level Expression of Secreted Glycoproteins in Transformed Lepidopteran Insect Cells Using a Novel Expression Vector"; December 20, 1998; <u>Biotechnology and Bioengineering</u> ; Vol. 60(6); pp. 656-663.			<input type="checkbox"/>
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/614,037
(Use as many sheets as necessary)				Filing Date	07/08/2003
				First Named Inventor	REITER et al.
				Art Unit	1636
				Examiner Name	N. VOGEL
Sheet	5	of	16	Attorney Docket Number	14693-0195

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	76	FAURE, T. et al.; "Stable Expression of Coagulation Factors FVIII and FIX in Recombinant Chinese Hamster Ovary Cells"; 1989; Meeting Info. 9 th General Meeting of the European Society for Animal Cell Technology; Knokke (Belgium); 1988; pp. 481-488.	<input type="checkbox"/>
	77	FIELD, R.P. et al.; "Production of a Chimeric Antibody for Tumour Imaging and Therapy From Chinese Hamster Ovary (CHO) and Myeloma Cells"; May 1990; <u>Proceedings of the 10th ESACT Meeting</u> ; pp. 742-744.	<input type="checkbox"/>
	78	FISCHER, B. et al.; "Comparison of N-Glycan Pattern of Recombinant Human Coagulation Factors II and IX Expressed in Chinese Hamster Ovary (CHO) and African Green Monkey (Vero) Cells"; 1996; <u>J. Thrombos. and Trombolys.</u> ; Vol. 3; pp. 57-62.	<input type="checkbox"/>
	79	FISCHER, B.E. et al.; "Biochemical and Functional Characterization of Recombinant von Willebrand Factor Produced on a Large Scale"; 1997; <u>CMLS</u> ; Vol. 53; pp. 943-950.	<input type="checkbox"/>
	80	FISCHER, B.E. et al.; "Structural Analysis of Recombinant von Willebrand Factor Produced at Industrial Scale Fermentation of Transformed CHO Cells Co-expressing Recombinant Furin"; 1995; <u>FEBS Letters</u> ; Vol. 375; pp. 259-262.	<input type="checkbox"/>
	81	FISCHER et al.; "Structural Analysis of Recombinant von Willebrand Factor: Identification of Hetero- and Homo-Dimers"; 1994; <u>FEBS Letters</u> ; Vol. 351; pp. 345-348.	<input type="checkbox"/>
	82	FRANEK, F. et al.; "Plant Protein Hydrolysates: Preparation of Defined Peptide Fractions Promoting Growth and Production in Animal Cells Cultures"; 2000; <u>Biotechnol. Prog.</u> ; Vol. 16(5); pp. 688-692.	<input type="checkbox"/>
	83	FRESHNEY, R.I.; "The Culture Environment: Substrate, Gas Phase, Medium, and Temperature"; Chapter 7 <u>In Culture of Animal Cells a Manual of Basic Technique</u> , 2 nd Edition; 1987; pp. 57-84.	<input type="checkbox"/>
	84	FRIEDMAN, J.S. et al.; "High Expression in Mammalian Cells Without Amplification"; April 1989; <u>Biotechnology</u> ; Vol. 7; pp. 359-362.	<input type="checkbox"/>
	85	GANDOR, C.; "Amplification and Expression of Recombinant Genes in Serum-Independent Chinese Hamster Ovary Cells"; 1995; <u>FEBS Letters</u> ; Vol. 377; pp. 290-294.	<input type="checkbox"/>
	86	GORFIEN, S.F. et al.; "Recombinant Protein Production by CHO Cells Cultured in a Chemically Defined Medium"; 1996; presented at JAACT, Yokohama: Japan; 16 pages.	<input type="checkbox"/>
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				<i>Complete if Known</i>	
				Application Number	10/614,037
				Filing Date	07/08/2003
				First Named Inventor	REITER et al.
				Art Unit	1636
				Examiner Name	N. VOGEL
Sheet	6	of	16	Attorney Docket Number	14693-0195

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	87	HALDANKAR, R. et al.; "Stable Production of a Human Growth Hormone Antagonist From CHO Cells Adapted to Serum-Free Suspension Culture"; 1999; <u>Biotechnol. Prog.</u> ; Vol. 15(3); pp. 336-346.			<input type="checkbox"/>
	88	HAM, R.G.; "Clonal Growth of Mammalian Cells in a Chemically Defined, Synthetic Medium"; 1965; <u>PNAS</u> ; Vol. 53; pp. 288-293.			<input type="checkbox"/>
	89	HARANT, H. et al.; "Two-Dimensional Electrophoresis as a Tool For Control of Quality and Consistency in Production Systems Using Animal Cells"; 1992; <u>Cytotechnology</u> ; Vol. 8; pp. 119-127.			<input type="checkbox"/>
	90	HARRISON, S. et al.; "The Manufacturing Process for Recombinant Factor IX"; April 1998; <u>Seminars in Hematology</u> ; Vol. 35(2), Suppl. 2; pp. 4-10.			<input type="checkbox"/>
	91	HASSELL, T. et al.; "Stability of Production of Recombinant Antibodies from Glutamine Synthetase Amplified CHO and NS0 Cell Lines"; 1992; <u>Animal Cell Technology: Developments, Processes and Products</u> , 11 th ESACT Meeting; pp. 42-47.			<input type="checkbox"/>
	92	HEIDEMANN, R. et al.; "The Use of Peptones as Medium Additives for High-Density Perfusion Cultures of Animal Cells"; Poster Presented at the 16th ESACT Meeting, April 25-29, 1999, Lugano, Switzerland; 3 pages.			<input type="checkbox"/>
	93	HEIDEMANN, R. et al.; "The Use of Peptones as Medium Additives for the Production of a Recombinant Therapeutic Protein in High Density Perfusion Cultures of Mammalian Cells"; 2000; <u>Cytotechnology</u> ; Vol. 32; pp. 157-167.			<input type="checkbox"/>
	94	HSIEH, C.M. et al.; "The Effect of Soy Protein Hydrolyzates on Fermentation by <i>Lactobacillus amylovorus</i> "; 1999; <u>Process Biochemistry</u> ; Vol. 34; pp. 173-179.			<input type="checkbox"/>
	95	INOUE, Y. et al.; "Production of Recombinant Human Monoclonal Antibody Using ras-Amplified BHK-21 Cells in a Protein-free Medium"; 1996; <u>Biosci. Biotech. Biochem.</u> ; Vol. 60(5); pp. 811-817.			<input type="checkbox"/>
	96	ITO, Y. et al.; "Protein-Free Cell Culture on an Artificial Substrate with Covalently Immobilized Insulin"; 1996; <u>Proc. Natl. Acad. Sci. USA</u> ; Vol. 93; pp. 3598-3601.			<input type="checkbox"/>
	97	JAN, D.C-H. et al.; "Peptone, a Low-Cost Growth-Promoting Nutrient for Intensive Animal Cell Culture"; <u>Cytotechnology</u> ; Vol. 16; pp. 17-26.			<input type="checkbox"/>
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/614,037
(Use as many sheets as necessary)				Filing Date	07/08/2003
				First Named Inventor	REITER et al.
				Art Unit	1636
				Examiner Name	N. VOGEL
Sheet	7	of	16	Attorney Docket Number	14693-0195

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	98	JIN, B.R. et al.; "Production Kinetics and Stability of a Transfectoma Cell Line Secreting Murine/Human Chimeric Antibody"; 1993; <u>Mol. Cells</u> ; Vol. 3; pp. 233-237.			<input type="checkbox"/>
	99	KADOURI, A. et al.; "Dynamic Changes in Cytokine Secretion by Stromal Cells During Prolonged Maintenance Under Protein-Free Conditions"; 1992; <u>International Journal of Cell Cloning</u> ; Vol. 10; pp. 299-308.			<input type="checkbox"/>
	100	KATINGER, H. et al.; "Long-Term Stability of Continuously Perfused Animal Cells Immobilized on Novel Macroporous Microcarriers"; 1996; <u>Adv. Molecul. Cell Biol.</u> ; Vol. 15A; pp. 193-207.			<input type="checkbox"/>
	101	KATSUTA, H. et al.; "Effects of Polyamines on the Proliferation of Mammalian Cells in Tissue Culture"; 1975; <u>The Japanese Journal of Experimental Medicine</u> ; Vol. 45(5); pp. 345-354.			<input type="checkbox"/>
	102	KATSUTA, H. and TAKAOKA, T.; "Amino Acid Requirements of a Substrain of Strain L Cells (Mouse Fibroblasts) in Protein-Free Chemically Defined Synthetic Media"; 1960; <u>Japan. J. Exp. Med.</u> ; Vol 30; pp. 235-259.			<input type="checkbox"/>
	103	KAUFMAN, K. et al.; "Effect of von Willebrand Factor Coexpression on the Synthesis and Secretion of Factor VIII in Chinese Hamster Ovary Cells"; 1989; <u>Molecul. Cellul. Biol.</u> ; Vol. 9(3); pp. 1233-1242.			<input type="checkbox"/>
	104	KEAY, L.; "Autoclavable Low Cost Serum-Free Cell Culture Media: the Growth of Established Cell Lines and Production of Viruses"; 1976; <u>Biotechnology and Bioengineering</u> ; Vol XVIII; pp. 363-382.			<input type="checkbox"/>
	105	KEAY, L.; "Autoclavable Low Cost Serum-Free Cell Culture Media. The Growth of L Cells and BHK Cells on Peptones"; 1975; <u>Biotechnology and Bioengineering</u> ; Vol. XVII; pp. 745-764.			<input type="checkbox"/>
	106	KEEN, M.J. and RAPSON, N.T.; "Development of a Serum-Free Culture Medium for the Large Scale Production of Recombinant Protein From a Chinese Hamster Ovary Cell Line"; 1995; <u>Cytotechnology</u> ; Vol. 17; pp. 153-163.			<input type="checkbox"/>
	107	KIM, S.J. et al.; "Characterization of Chimeric Antibody Producing CHO Cells in the Course of Dihydrofolate Reductase-Mediated Gene Amplification and Their Stability in the Absence of Selective Pressure"; April 5, 1998; <u>Biotechnology and Bioengineering</u> ; Vol. 58(1); pp. 73-84.			<input type="checkbox"/>
	108	KIM, N.S. et al.; "Clonal Variability Within Dihydrofolate Reductase-Mediated Gene Amplified Chinese Hamster Ovary Cells: Stability in the Absence of Selective Pressure"; December 20, 1998; <u>Biotechnology and Bioengineering</u> ; Vol. 60(6); pp. 679-688.			<input type="checkbox"/>
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/614,037
(Use as many sheets as necessary)				Filing Date	07/08/2003
				First Named Inventor	REITER et al.
				Art Unit	1636
				Examiner Name	N. VOGEL
Sheet	8	of	16	Attorney Docket Number	14693-0195

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	109	KWON, M.S. et al.; "Use of Plant-Derived Protein Hydrolysates for Enhancing Growth of <i>Bombyx mori</i> (Silkworm) Insect Cells in Suspension Culture"; 2005; <u>Biotechnology and Applied Biochemistry</u> ; Vol. 42; pp. 1-7.		
	110	LEE, K.H. et al.; "Deregulated Expression of Cloned Transcription Factor E2F-1 in Chinese Hamster Ovary Cells Shifts Protein Patterns and Activates Growth in Protein-Free Medium"; 1996; <u>Biotechnol. Bioeng.</u> ; Vol. 50; pp. 273-279.		
	111	LUCHETTE, C. et al.; "Isolation and Characterization of a CHO Cell Line Expressing rhFSH in Low Protein and Protein-Free Media"; 1997; <u>Animal Cell Technology</u> ; pp. 669-674.		
	112	MERTEN, O.-W. et al.; "Production of influenza Virus In Serum-Free Mammalian Cell Cultures"; 1999; <u>Dev. Biol. Stand.</u> ; Vol. 98; pp. 23-37.		
	113	MERTEN, O.-W. et al.; "The New Medium MDSS2N, Free of Any Animal Protein Supports Cell Growth and Production of Various Viruses"; 1999; <u>Cytotechnology</u> ; Vol. 30; pp. 191-201.		
	114	MERTEN, O.-W.; "Safety Issues of Animal Products Used in Serum-Free Media"; 1999; <u>Dev. Biol. Stand.</u> ; Vol. 99; pp. 167-180.		
	115	MIYAJI, H. et al.; "Efficient Expression of Human Beta-interferon in Namalwa KJM-1 Cells Adapted to Serum-free Medium by a dhfr Gene Coamplification Method"; 1990; <u>Cytotechnology</u> ; Vol. 4; pp. 173-180.		
	116	MIYAJI, H. et al.; "Expression of Human Beta-interferon in Namalwa KJM-1 Which Was Adapted to Serum-free Medium"; 1990; <u>Cytotechnology</u> ; Vol. 37; pp. 133-140.		
	117	MOTZ, M. et al.; "Expression of the Epstein-Barr Virus Major Membrane Proteins in Chinese Hamster Ovary Cells"; 1986; <u>Gene</u> ; Vol. 44(2-3); pp. 353-359; Abstract, 1 page.		
	118	MURHAMMER, D.W. and GOOCHE, C.F.; "Structural Features of Nonionic Polyglycol Polymer Molecules Responsible for the Protective Effect in Sparged Animal Cell Bioreactors"; 1990; <u>Biotechnol. Prog.</u> ; Vol. 6; pp. 142-146.		
	119	NILSSON, K. et al.; "Microcarrier Culture of Recombinant Chinese Hamster Ovary Cells for Production of Human Immune Interferon and Human Tissue-Type Plasminogen Activator"; 1988; <u>Appl. Microbiol. Biotechnol.</u> ; Vol. 27; pp. 366-371.		
Examiner Signature				Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/614,037
(Use as many sheets as necessary)				Filing Date	07/08/2003
				First Named Inventor	REITER et al.
				Art Unit	1636
				Examiner Name	N. VOGEL
Sheet	9	of	16	Attorney Docket Number	14693-0195

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	120	NYBERG, G.B. et al.; "Metabolism of Peptide Amino Acids by Chinese Hamster Ovary Cells Grown in a Complex Medium"; February 5, 1999; <u>Biotechnology and Bioengineering</u> ; Vol. 62(3); pp. 324-335.			<input type="checkbox"/>
	121	OCHIAI, M. et al.; "Endotoxin Content in <i>Haemophilus influenzae</i> Type b Vaccine"; 2004; <u>Jpn. J. Infect. Dis.</u> ; Vol. 57; pp. 58-59.			<input type="checkbox"/>
	122	OGATA, M. et al.; "High-Level Expression of Recombinant Human Soluble Thrombomodulin In serum-Free Medium by CHO-K1 Cells"; 1993; <u>Appl. Microbiol. Biotechnol.</u> ; Vol. 38; pp. 520-525.			<input type="checkbox"/>
	123	PAK, S.C.O. et al.; "Super-CHO - A Cell Line Capable of Autocrine Growth Under Fully Defined Protein-Free Conditions"; 1996; <u>Cytotechnology</u> ; Vol. 22; pp. 139-146.			<input type="checkbox"/>
	124	PATERSON, T. et al.; "Approaches to Maximizing Stable Expression of α 1-Antitrypsin in Transformed CHO Cells"; 1994; <u>Appl. Microbiol. Biotechnol.</u> ; Vol. 40; pp. 691-698.			<input type="checkbox"/>
	125	PU, H. et al.; "Rapid Establishment of High-Producing Cell Lines Using Dicistronic Vectors with Glutamine Synthetase as the Selection Marker"; 1998; <u>Molecular Biotechnology</u> , Vol. 10; pp. 17-25.			<input type="checkbox"/>
	126	QI, Y.M. et al.; "Evaluation of a Simple Protein Free Medium That Supports High Levels of Monoclonal Antibody Production"; 1996; <u>Cytotechnology</u> ; Vol. 21; pp. 95-109.			<input type="checkbox"/>
	127	RASMUSSEN, B. et al.; "Isolation, Characterization and Recombinant Protein Expression in Veggie-CHO: A Serum-Free CHO Host Cell Line"; 1998; <u>Cytotechnology</u> ; Vol. 28; pp. 31-42.			<input type="checkbox"/>
	128	REITER, M. et al.; "Flow Cytometry and Two-Dimensional Electrophoresis (2-DE) for System Evaluation of Long Term Continuous Perused Animal Cell Cultures in Macroporous Beads"; 1992; <u>Cytotechnology</u> ; Vol. 9; pp. 247-253.			<input type="checkbox"/>
	129	RENNER, W.A. et al.; "Recombinant Cyclin E Expression Activates Proliferation and Obviates Surface Attachment of Chinese Hamster Ovary (CHO) Cells in Protein-Free Medium"; August 1995; <u>Biotechnology and Bioengineering</u> ; Vol. 47; pp. 476-482.			<input type="checkbox"/>
	130	RYLL, T. et al.; "Production of Recombinant Human Interleukin-2 with BHK Cells in a Hollow Fibre and a Stirred Tank Reactor with Protein-Free Medium"; 1990; <u>Journal of Biotechnology</u> ; Vol. 14; pp. 377-392.			<input type="checkbox"/>
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete If Known	
				Application Number	10/614,037
				Filing Date	07/08/2003
				First Named Inventor	REITER et al.
				Art Unit	1636
				Examiner Name	N. VOGEL
Sheet	10	of	16	Attorney Docket Number	14693-0195

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
	131	SCHARFENBERG, K. and WAGNER, R.; "A Reliable Strategy for the Achievement of Cell Lines Growing in Protein-Free Medium"; 1995; <u>Animal Cell Technology: Developments towards the 21st Century</u> ; pp. 619-623.				<input type="checkbox"/>
	132	SCHLAEGER, E.J.; "The Protein Hydrolystate, Primatone RL, is a Cost-Effective Multiple Growth Promoter of Mammalian Cell Culture in Serum-Containing and Serum-Free Media and Displays Anti-apoptosis Properties"; 1996; <u>Journal of Immunological Methods</u> ; Vol. 194; pp. 191-199.				<input type="checkbox"/>
	133	SCHLOKAT, U. et al.; "Herstellung und Charakterisierung von rekombinantern von Willebrand-Faktor zur Therapeutischen Anwendung"; 1995; <u>26th Hämophile-Symposium Hamburg</u> ; pp. 147-158.				<input type="checkbox"/>
	134	SCHLOKAT, U. et al.; "Production of Highly Homogeneous and Structurally Intact Recombinant von Willebrand Factor Multimers by Furin-Mediated Propeptide Removal <i>in vitro</i> "; 1996; <u>Biotechnol. Appl. Biochem.</u> ; Vol. 24; pp. 257-267.				<input type="checkbox"/>
	135	SCHNEIDER, Y.-J.; "Optimisation of Hybridoma Cell Growth and Monoclonal Antibody Secretion in a Chemically Defined, Serum- and Protein-Free Culture Medium"; 1989; <u>Journal of Immunological Methods</u> ; Vol. 116; pp. 65-77.				<input type="checkbox"/>
	136	SINACORE, M.S. et al.; "CHO DUKX Cell Lineages Preadapted to Growth in Serum-Free Suspension Culture Enable Rapid Development of Cell Culture Processes for the Manufacture of Recombinant Proteins"; 1996; <u>Biotechnol. Bioeng.</u> ; Vol. 52; pp. 518-528.				<input type="checkbox"/>
	137	STOLL, T.S. et al.; "Effects of Culture Conditions on the Production and Quality of Monoclonal IgA"; August 15, 1997; <u>Enzyme and Microbial Technology</u> ; Vol. 21; pp. 203-211.				<input type="checkbox"/>
	138	SUNSTROM, N.-A. et al.; "Recombinant Insulin-like Growth Factor-I (IGF-I) Production in Super-CHO Results In the Expression of IGF-I Receptor and IGF Binding Protein 3"; 1998; <u>Cytotechnology</u> ; Vol. 28; pp. 91-99.				<input type="checkbox"/>
	139	TAKAHASHI, M. et al.; "Production of Murine Monoclonal Antibodies in Protein Free Medium"; 1997; <u>Animal Cell Technology: Basic & Applied Aspects</u> ; Vol. 8; pp. 167-171.				<input type="checkbox"/>
	140	TAYLOR, W.G. et al.; "Studies on a Serum Substitute for Mammalian Cells in Culture. I. Biological Efficacy of Whole and Fractionated Peptone Dialysate (36086)"; 1972; <u>Proc. Soc. Exp. Biol. Med.</u> ; Vol. 139; pp. 96-99.				<input type="checkbox"/>

Examiner Signature		Date Considered
--------------------	--	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
Sheet	11	of	16	Application Number	10/614,037
				Filing Date	07/08/2003
				First Named Inventor	REITER et al.
				Art Unit	1636
				Examiner Name	N. VOGEL
				Attorney Docket Number	14693-0195

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	141	TECCE, M.F. and TERRANA, B.; "HighYield and High-Degree Purification of Human α -Fetoprotein Produced by Adaptation of the Human Hepatoma Cell Line HEP G2 in a Serum-Free Medium"; 1988; <u>Analytical Biochemistry</u> ; Vol. 169; pp. 306-311.	<input type="checkbox"/>	
	142	TEIGE, M. et al.; "Problems with Serum-Free Production of Antithrombin III Regarding Proteolytic Activity and Product Quality"; 1994; <u>Journal of Biotechnology</u> ; Vol. 34; pp. 101-105.	<input type="checkbox"/>	
	143	WERNER, R.G. et al.; "Safety and Economic Aspects of Continuous Mammalian Cell Culture"; 1992; <u>Journal of Biotechnology</u> ; Vol. 22; pp. 51-68.	<input type="checkbox"/>	
	144	YAMAUCHI, T. et al.; "Production of Human Antithrombin-III in a Serum-Free Culture of CHO Cells"; 1992; <u>Biosci. Biotech. Biochem.</u> ; Vol. 56(4); pp. 600-604.	<input type="checkbox"/>	
	145	YIN, Z. et al.; "Sensitivity of 3T3 Cells to Low Serum Concentration and the Association Problems of Serum Withdrawal"; 1994; <u>Cell Biology International</u> ; Vol. 18(1); pp. 39-46.	<input type="checkbox"/>	
	146	ZANG, M. et al.; "Production of Recombinant Proteins in Chinese Hamster Ovary Cells Using a Protein-Free Cell Culture Medium"; 1995; <u>Biotechnology</u> ; Vol. 13; pp. 389-392.	<input type="checkbox"/>	
	147	ZANG-GANDOR, M.O.; "Improved Transfection of CHO Cells Using Endotoxin-Free Plasmid DNA"; <u>QIAGEN News</u> ; 1997; Vol. 4; pp. 1, 16-18.	<input type="checkbox"/>	
	148	BD Bionutrients TM ; Technical Manual Advanced Bioprocessing Third Edition Revised October 2006, pp. 1-67.	<input type="checkbox"/>	
	149	Biochrom AG; Dulbecco's MEM (DMEM) Formulation Information, 1 page.	<input type="checkbox"/>	
	150	Biochrom AG; Dulbecco's MEM Formulation Information (German Version), 1 page.	<input type="checkbox"/>	
	151	Biochrom AG; HAM's F-12 Medium Formulation Information, 1 page.	<input type="checkbox"/>	
Examiner Signature				Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
				Application Number	10/614,037
				Filing Date	07/08/2003
				First Named Inventor	REITER et al.
				Art Unit	1636
				Examiner Name	N. VOGEL
Sheet	12	of	16	Attorney Docket Number	14693-0195

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	152	Biochrom AG; ISCOVE's Medium Formulation Information (German Version), 1 page.	<input type="checkbox"/>
	153	Biochrom AG; RPMI 1640 Medium Formulation Information (German Version), 1 page.	<input type="checkbox"/>
	154	Biochrom AG; Dulbecco's MEM/HAM's F12 (1:1) Formulation Information (German Version), 1 page.	<input type="checkbox"/>
	155	Cambrex; Classical Media Formulations, specifically MEM Product Information, 1 page.	<input type="checkbox"/>
	156	Deftown Specialties; Peptone Selection Guide for Diagnostic and Fermentation Nutrients, 1994, 4 pages.	<input type="checkbox"/>
	157	Extract from Hauser, H. and Wagner, R. eds.; <u>Mammalian Cell Biotechnology in Protein Production</u> ; 1997; Walter de Gruyter, Berlin; pp. 33-137.	<input type="checkbox"/>
	158	Extract from Quest International; "Sheffield Series" Products Catalogue, 13 pages.	<input type="checkbox"/>
	159	Kerry Bio-Science; Pharma Ingredients Site for Hydrolysates, 4 pages.	<input type="checkbox"/>
	160	Minutes of the Oral Proceedings to EP 99 939 251.7, 4 pages.	<input type="checkbox"/>
	161	Page from the Quest International Technical Manual on Hydrolysates, 1988.	<input type="checkbox"/>
	162	Product Information "Bacto™ TC Yeastolate TC Yeastolate, UF, 2 pages.	<input type="checkbox"/>
Examiner Signature			Date Considered

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/614,037
(Use as many sheets as necessary)				Filing Date	07/08/2003
				First Named Inventor	REITER et al.
				Art Unit	1636
				Examiner Name	N. VOGEL
Sheet	13	of	16	Attorney Docket Number	14693-0195

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	163	Quest International; "Protein Derived Peptide Mixtures can Effectively Replace Serum, Glutamine and Other Free Amino Acids in Cell Culture Media"; November 1998; Research Disclosure; pp. 1474-1476.			<input type="checkbox"/>
	164	Quest International; Bioproducts Group HY-SOY®, Product Information, 1995, 1 page.			<input type="checkbox"/>
	165	Quest International, Bioproducts Group HY-SOY 2®, Product Information, 1995, 1 page.			<input type="checkbox"/>
	166	Quest International; Bioproducts Group HY-SOY®, Product Information, 1998, 2 pages.			<input type="checkbox"/>
	167	Quest International; HyPep® 1510 (IPL:5Z10493) Product Information, 2 pages.			<input type="checkbox"/>
	168	Quest International; Pharma Ingredients Site with Product Information for HyPep® 1510 and Hy-Soy®, 11 pages.			<input type="checkbox"/>
	169	Quest International; Product Information; www.sheffield-products.com ; accessed on November 18, 2003; 14 pages.			<input type="checkbox"/>
	170	SAFC Biosciences™; Dulbecco's Modified Eagle's Medium/Ham's Nutrient Mixture F12 Product Information, 2006, 2 pages.			<input type="checkbox"/>
	171	SAFC Biosciences™; RPMI 1640 Medium Modified Product Information, 2006, 2 pages.			<input type="checkbox"/>
	172	Sigma®; Biochemicals Organic Compounds Diagnostic Reagents Catalogue, 1995, 6 pages.			<input type="checkbox"/>
	173	Sigma-Aldrich; DME/Nutrient Mixture F12 Ham Product Information, 8 pages.			<input type="checkbox"/>
Examiner Signature				Date Considered	

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/614,037
(Use as many sheets as necessary)				Filing Date	07/08/2003
				First Named Inventor	REITER et al.
				Art Unit	1636
				Examiner Name	N. VOGEL
Sheet	14	of	16	Attorney Docket Number	14693-0195

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	174	Sigma-Aldrich; Dulbecco's Modified Eagle's Medium (DME)/Ham's Nutrient Mixture F-12, Product Information, 2 pages.			<input type="checkbox"/>
	175	Sigma-Aldrich; IPL-41 Insect Medium Product Information, 1 page.			<input type="checkbox"/>
	176	Sigma-Aldrich; Minimum Essential Medium Eagle (MEM), Product Information, 6 pages.			<input type="checkbox"/>
	177	Sigma-Aldrich; Minimum Essential Medium Eagle, Joklik Modification, Specification Sheet, 1 page.			<input type="checkbox"/>
	178	Sigma-Aldrich; P1265 N-Z Soy Peptone Product Detail, 1 page.			<input type="checkbox"/>
	179	Sigma-Aldrich; P6463 Peptone Hy-Soy®T Product Detail, 1 page.			<input type="checkbox"/>
	180	AstraZeneca AB Opposition Brief to European Patent No.1200561 dated March 14, 2007.			<input type="checkbox"/>
	181	Bayer Healthcare AG Opposition Brief to European Patent No.1200561 dated March 13, 2007.			<input type="checkbox"/>
	182	Bloceuticals Arzneimittel AG Opposition Brief to European Patent No.1200561 dated March 14, 2007.			<input type="checkbox"/>
	183	Biogen IDEC MA, Inc. Opposition Brief to European Patent No.1200561 dated March 14, 2007.			<input type="checkbox"/>
	184	Campina Nederland Holding B.V. Opposition Brief to European Patent No. 1220893 dated March 21, 2007.			<input type="checkbox"/>
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete If Known	
Sheet	15	of	16	Application Number	10/614,037
				Filing Date	07/08/2003
				First Named Inventor	REITER et al.
				Art Unit	1636
				Examiner Name	N. VOGEL
				Attorney Docket Number	14693-0195

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	185	F. Hoffmann-La Roche AG Opposition Brief to European Patent No.1200561 dated March 13, 2007.	<input type="checkbox"/>
	186	F. Hoffmann-La Roche AG Opposition Brief to European Patent No. 1220893 dated March 27, 2007.	<input type="checkbox"/>
	187	Kerry Ingredients (UK) Limited Opposition Brief to European Patent No. 1220893 dated March 21, 2007.	<input type="checkbox"/>
	188	Maxygen Inc. Opposition Brief to European Patent No.1200561 dated March 14, 2007.	<input type="checkbox"/>
	189	Maxygen, Inc. Opposition Brief to European Patent No. 1220893 dated March 20, 2007.	<input type="checkbox"/>
	190	Declaration of Dr. Ricardo Matanguhan in support of Maxygen, Inc. Opposition Brief to European Patent No. 1220893 dated March 20, 2007 (including Annexes A and B).	<input type="checkbox"/>
	191	Declaration of Dr. Ruediger Heidemann in support of Maxygen, Inc. Opposition Brief to European Patent No. 1220893 dated March 20, 2007 (including Annexes A-F).	<input type="checkbox"/>
	192	Merch Serono International S.A. Opposition Brief to European Patent No.1200561 dated March 12, 2007.	<input type="checkbox"/>
	193	Merck Serono International S.A. Opposition Brief to European Patent No. 1220893 dated March 20, 2007.	<input type="checkbox"/>
	194	N.V. Organon Opposition Brief to European Patent No.1200561 dated March 14, 2007.	<input type="checkbox"/>
	195	Novartis AG Opposition Brief to European Patent No.1200561 dated March 14, 2007.	<input type="checkbox"/>
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/614,037
(Use as many sheets as necessary)				Filing Date	07/08/2003
				First Named Inventor	REITER et al.
				Art Unit	1636
				Examiner Name	N. VOGEL
Sheet	16	of	16	Attorney Docket Number	14693-0195

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	196	Novartis AG Opposition Brief to European Patent No. 1220893 dated March 21, 2007.	<input type="checkbox"/>
	197	Novo Nordisk A/S Opposition Brief to European Patent No. 1200561 dated March 14, 2007.	<input type="checkbox"/>
	198	Novo Nordisk A/S Opposition Brief to European Patent No. 1220893 dated March 21, 2007.	<input type="checkbox"/>
	199	Sigma-Aldrich Co. Opposition Brief to European Patent No. 1220893 dated March 21, 2007.	<input type="checkbox"/>
	200	Wyeth Opposition Brief to European Patent No. 1200561 dated March 14, 2007.	<input type="checkbox"/>

Examiner Signature		Date Considered
--------------------	--	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.